Valentina Guarneri, Carlo Alberto Giorgi, Saverio Cinieri, Carmelo Bengala, Gabriella Mariani, Giancarlo Bisagni, Antonio Frassoldati, Claudio Zamagni, Costanza De Rossi, Vito Amoroso, Claudia Andreetta, Antonella Ferro, Alberto Zambelli, Stefania Gori, Ornella Garrone, Maria Vittoria Dieci, Laura Orlando, Ilaria Pastina, Teresa Beninato, Gabriella Moretti, Elisa Genovesi, Margherita Cinefra, Roberto Vicini, Giovanna Magni, Gian L De Salvo, PierFranco Conte
BACKGROUND: Despite endocrine therapy being the mainstay of treatment for hormone receptor positive (HR+)/HER2- metastatic breast cancer, patients at risk of visceral crisis or doubt for endocrine sensitivity are still offered first-line chemotherapy. Maintenance hormonal therapy is generally offered at the discontinuation of chemotherapy. The MAINtenance Afinitor study is a randomised, phase III trial comparing maintenance everolimus combined with aromatase inhibitors (AIs) versus AI monotherapy in patients with disease control after first-line chemotherapy...
September 2021: European Journal of Cancer